Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®)

Summary Omalizumab (Xolair®) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental dermatology 2018-07, Vol.43 (5), p.573-576
Hauptverfasser:	Hughes, J. D. M., Olynyc, T., Chapdelaine, H., Segal, L., Miedzybrodzki, B., Ben‐Shoshan, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Allergic Agents - therapeutic use Child, Preschool Children Humans Immunoglobulin E Immunotherapy Male Mastocytosis Mastocytosis, Cutaneous - drug therapy Monoclonal antibodies Omalizumab - therapeutic use Skin cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Omalizumab (Xolair®) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.
ISSN:	0307-6938 1365-2230
DOI:	10.1111/ced.13408